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A B S T R A C T
Objectives: The aim of the merit-3 study was to determine the safety and performance of the BioMime
Sirolimus-Eluting Coronary Stent System (SES) in all-comer patients with coronary artery disease (CAD)
in one-year clinical follow-up period.
Methods: The meriT-3 was a multi-centre, observational, post-marketing study conducted in
1161 patients with CAD who were implanted with BioMime SES at 15 sites in India. The primary
endpoint was major adverse cardiac event (MACE) at one year deﬁned as the composite of cardiac death,
myocardial infarction (MI) and target lesion revascularization (TLR). Clinical follow-up was performed at
1, 6, and 12 months. Major adverse cardiac event occurred at 30 days and subsequently at 6 months and
at long-term follow-up of 1 year was analyzed.
Results: MACE observed at 1 and 6 months follow-up was 16 (1.38%) and 21 (1.83%) respectively.
Cumulative 1 year MACE was 26 (2.35%) with 16 (1.39%) all cause death, 4 (0.35%) MI and 6 (0.52%) TLR.
In addition, ST was observed in 1 (0.09%) patient.
Conclusions: The present study suggests that the BioMime SES is safe and effective in a ‘‘real-world’’, all-
comers CAD patients, indicating low rates of MACE.
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 This study suggests that the BioMime SES is safe and effective in a
‘‘real-world’’, all-comers CAD patients, indicating low rates of
MACE and ST.
What is already known?
 First-generation DES was linked with late ST and was created on
bulky stent platforms with questionable deliverability and
polymer biocompatibility.
1. Introduction
Coronary artery disease (CAD) is the leading cause of mortality
across the globe.1 For the last few years, the drug eluting stents
(DES) have become the treatment of choice for the vast majority of
patients undergoing percutaneous coronary intervention (PCI).2
The DES have been used in various clinical and anatomical
scenarios due to their reduction in restenosis rates and the need for
repeat revascularisation.3,4 However, the ﬁrst-generation DES
were associated with an increased risk of late events including
stent thrombosis (ST) and late restenosis. Efforts to prevent these
risks have included prolongation of antiplatelet therapy, and
improvement in stent platforms, polymer carriers, and drug
selection.3 Although the mechanism of thrombotic events is not
completely clariﬁed, hypersensitivity reaction to the permanent/
non degradable polymer is one of the possible explanation in this
composite equation.4 The residual polymers of DES (coated with
durable polymer) have been accused of instigating inﬂammatory
reaction, which delayed healing and re-endothelialization of
the DES.5–10
The use of the biodegradable polymer has the potential to
reduce the sustained inﬂammatory responses of the arterial wall,
facilitating re-endothelialization and minimizing the risk of
thrombus formation and late restenosis.3 Thus, the DES such as
BioMime Sirolimus-Eluting Coronary Stent System (Meril Life
Sciences Pvt. Ltd., Gujarat, India) has been developed with an aim
to reduce neointimal hyperplasia.
The BioMime Sirolimus-Eluting Coronary Stent System (SES) is
a CE approved biodegradable polymer. The BioMime SES is
comprised of poly-L-lactic and poly-lactic-co-glycolic acids. The
BioMime SES is built on NexGen, an ultra-thin (65 mm) cobalt–
chromium platform with a hybrid cell design with an aim to reduce
intra-arterial injury.
The sirolimus formulated with the biodegradable polymer
releases into the treated vessel during 30–40 days after stent
implantation.11 The ﬁrst-in-man study of BioMime SES has
demonstrated excellent performance in CAD patients including
high procedural success (100%) and clinical performance.12
Consequently, the purpose of the present study was to
determine the safety and performance of the BioMime SES in
all-comer patients with CAD at one-year clinical follow-up.
2. Objective
The aim of the meriT-3 study was to determine the safety and
performance of the BioMime SES in all-comer patients with CAD.
3. Material and methods
3.1. Device description
The BioMime SES (Meril Life Sciences Pvt. Ltd., Gujarat, India) is
built on NexGen, an ultra-thin (65 mm) cobalt–chromium platform
with a hybrid cell design. This design is a mix of close cells at theedges and open cells in the mid segment. The SES is coated with
1.25 mg sirolimus/mm2 of stent surface area. The biodegradable
polymer, which acts as a drug carrier, is a thin copolymer
formulation combining two biodegradable components namely
poly-L-lactic and poly-lactic-co-glycolic acids. The BioMime SES
was available in sizes of 8, 13, 16, 19, 24, 29, 32, 37, 40, 44, 48 mm
lengths and diameters of 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00,
4.50 mm.
3.2. Study design and population
The meriT-3 study was conducted at 15 centres in India; with a
total of 1161 patients were included in this study. This was a post-
marketing study of all-comer patients who underwent stenting for
the management of CAD using BioMime SES. The study was
performed with the approval of the local ethics committee.
Informed, written consent was obtained from all study partici-
pants. The PCI procedures were performed according to current
standard guidelines.13 Clinical and angiographic data from all the
patients who were treated with BioMime SES were observed in this
study. The clinical/telephonic follow-up was performed at the
following time points: 30 days, 6 months, and 12 months after
discharge. All the serious adverse events were evaluated by
Adjudication committee.
All patients received dual antiplatelet therapy (DAPT) including
a loading dose of aspirin as per investigator’s discretion. Aspirin
was coupled with clopidogrel, prasugrel, or ticagrelor. The
procedural anticoagulation was achieved either with heparin or
bivalirudin. The intra-procedural administration of glycoprotein
IIb/IIIa inhibitor was at the investigator’s discretion. All patients
were recommended the DAPT (aspirin; 75–300 mg daily indeﬁ-
nitely and clopidogrel; 75 mg daily or prasugrel; 10 mg daily or
ticagrelor; 90 mg twice daily for at least 12 months) after the
procedure.
3.3. Deﬁnitions and end points
Major adverse cardiac event (MACE) was deﬁned as the
composite of cardiac death, MI, target lesion revascularization
(TLR). All cause of death were considered cardiac unless a non-
cardiac cause could be established clearly, either by clinical
assessment or by pathological study. The ST was classiﬁed
according to the deﬁnitions of the Academic Research Consor-
tium.14 Procedural success was deﬁned as successful stent
placement at the desired position with <30% residual stenosis.15
At follow-up, data were collected relating to current clinical status,
any prior hospitalization and occurrence of any MACE. The primary
endpoint was MACE at 1-month and 6-month follow-up and
secondary endpoints were MACE at 1-year follow-up.
3.4. Statistical analysis
Categorical data were presented as counts and percentages. All
clinical and angiographic continuous variables were presented as a
mean  standard deviation. The time-to-event curve was presented
as per the Kaplan–Meier method. All data were processed using the
Statistical Package for Social Sciences, version 15 (SPSS, Chicago, IL,
USA).
4. Results
4.1. Baseline demographics characteristics
The analysis consists of baseline clinical data and consecutive
follow-up data collected at 1 month, 6 months, and 12 months. Of
1161 patients enrolled in the study, 922 (79.4%) were male, and
Table 2
Lesion and procedural characteristics.
Characteristics Patients = 1161/lesions = 1312
Target vessel location
Left anterior descending, n (%)
768 (58.5%)
Right coronary artery, n (%) 324 (24.7%)
Left circumﬂex, n (%) 194 (14.8%)
Others, n (%) 26 (2.0%)
Total number of patient treated lesions, n 1312
Treated with 1 lesion, n (%) 1029 (88.6%)
Treated with 2 lesions, n (%) 114 (9.8%)
Treated with 3 lesions, n (%) 17 (1.5%)
Treated with 4 lesions, n (%) 1 (0.1%)
Average number of lesions per patient 1.1  0.4
Reference vessel diameter (mean  SD, mm) 3  0.4
Lesion length (mean  SD, mm) 18.5  8.2
Diameter stenosis (mean  SD, %) 89.9  7.3
Type of stenosis
De novo, n (%) 1300 (99.1%)
In-Stent, n (%) 9 (0.7%)
Bifurcation, n (%) 3 (0.2%)
Type of lesion
Long, n (%) 166 (12.6%)
Diffused, n (%) 933 (71.1%)
Thrombus, n (%) 86 (6.6%)
CTO, n (%) 117 (8.9%)
Calciﬁed, n (%) 10 (0.8%)
Pre-procedural TIMI ﬂow grade
0, n (%) 178 (13.5%)
I, n (%) 645 (49.2%)
II, n (%) 458 (34.9%)
III, n (%) 31 (2.4%)
Pre-dilatation, n (%) 961 (73.2%)
Access site location, n 1161
Femoral, n (%) 782 (67.4%)
Radial, n (%) 379 (32.6%)
Average number of stents per patient 1.0  0.1
Average number of stents per lesion 1.0  0.1
Average stent length (mean  SD, mm) 23.1  8.4
Average stent diameter (mean  SD, mm) 3.0  0.4
CTO – chronic total occlusion, TIMI – thrombolysis in myocardial infarction.
Table 1
Demographic and baseline characteristics.
Characteristics BioMime Sirolimus
Eluting Coronary
Stent n = 1161 patients
Patient demographics
Age (mean  SD, yrs) 56.4  10.3
Male, n (%) 922 (79.4%)
Baseline medical history
History of diabetes mellitus, n (%) 477 (41.1%)
History of hypertension, n (%) 609 (52.5%)
History of hyperlipidemia, n (%) 66 (5.7%)
Smoker, n (%) 180 (15.5.0%)
Family history of coronary artery disease, n (%) 135 (11.6%)
Cardiac history
Previous MI, n (%) 159 (13.7%)
Previous PCI, n (%) 38 (3.3%)
Previous CABG, n (%) 17 (1.5%)
Cardiac status before index procedure
Anginal status
Asymptomatic, n (%) 155 (13.4%)
MI, n (%) 295 (25.4%)
Stable angina, n (%) 124 (10.7%)
Unstable angina, n (%) 587 (50.6%)
Type of PCI
PAMI, n (%) 148 (12.7%)
Facilitated, n (%) 1013 (87.3%)
CABG – coronary artery bypass grafting, MI – myocardial infarction, PCI –
percutaneous coronary intervention, PAMI – primary angioplasty in myocardial
infarction.
Table 3
Major adverse cardiac events at in-hospital stay, 1-month, 6-month and 1-year
follow-up.
Events In Hospital
n = 1161
1 month
n = 1152
6 month
n = 1147
12 month
n = 1147
All cause of death, n (%) 7 (0.60%) 12 (1.04%) 13 (1.13%) 16 (1.39%)
MI, n (%) 2 (0.17%) 3 (0.26%) 4 (0.35%) 4 (0.35%)
TLR, n (%) 0 1 (0.09%) 4 (0.35%) 6 (0.52%)
TVR, n (%) 0 0 1 (0.09%) 1 (0.09%)
Stent thrombosis, n (%) 1 (0.09%) 1 (0.09%) 1 (0.09%) 1 (0.09%)
Total MACE, n (%) 9 (0.77%) 16 (1.38%) 21 (1.83%) 26 (2.35%)
MI – myocardial infarction, TLR – target lesion revascularization, TVR – target vessel
revascularization, MACE – major adverse cardiac events.
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patients are outlined in Table 1. There was a history of diabetes in 477
(41.1%) patients, hypertension in 609 (52.5%), hyperlipidemia in 66
(5.7%), and family history of CAD in 135 (11.6%) patients. Of
1161 patients, 50.6% (587) patients were included and treated with
a diagnosis of unstable angina. Among 1161, 180 (15.5%) patients
were Smoker and 159 (13.7%) patients had previous MI. Baseline
lesion characteristics are mentioned in Table 2.
4.2. Clinical and angiographic outcomes
The composite of MACE rates at 30-day, 6-month, and 12-
month follow-up was 1.38%, 1.83% and 2.35%, respectively. The
summary of MACE during 1-year study period is presented in
Table 3. Total 26 (2.35%) patients experienced MACE during 1 year.
Of which, 16 (1.39%) were all cause death, 4 (0.35%) were MI and 6
(0.52%) were TLR. Furthermore, 1 (0.09%) patient had target vessel
revascularization (TVR) and only 1 (0.09%) patient had an
incidence of ST. The time-to-event analysis performed by
Kaplan–Meier method was found to be 97.65% (Fig. 1).
Baseline lesion characteristics are mentioned in Table 2. An
analysis of baseline angiography revealed that 88.6% of patients
had single lesions who were treated with BioMime stent. The mean
lesion length was 18.5 mm and mean pre-procedural diameter
stenosis was 89.9%. The most prevalent target vessel was left
anterior descending (LAD) artery (58.5%) and 71.1% of lesions were
diffused. The average number of lesions was 1.1 per patient. The
average stent length was 23.1  8.4 mm and average stent diameter
was 3.0  0.4. A total of 1326 BioMime stents were implanted (ratio of
1.14 stents/patient which is a reﬂection of real-world population).
5. Discussion
In this retrospective study, the BioMime SES has demonstrated
excellent performance in CAD patients including high procedural
success and clinical performance. The patient population had high
rates of diabetes (41.1%) and hypertension (52.5%). In this study weobserved the BioMime SES, which is based on an ultra-thin cobalt–
chromium platform with a hybrid cell design with an aim of
optimizing performance of BioMime SES. The thin struts allow the
production of stents with an extremely low proﬁle that helps in
device deliverability and ﬂexibility. First-generation DES was
linked with late ST16,17 and was created on bulky stent platforms
with questionable deliverability and polymer biocompatibility.18
The ultra thin novel BioMime SES stent design allows for a
morphologically-mediated expansion due to a hybrid cell design
structure (open cell conﬁguration in the centre and closed at the
edges). This method of expansion eliminates the classic dog-
boning observed with the conventional designs and also ensures
Fig. 1. Time-to-event curve at up to 1-year follow-up by Kaplan–Meier method.
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Therefore, the BioMime SES demonstrated complete wall apposi-
tion and thus lead to rapid endothelialisation. BioMime SES was
designed keeping in mind that the DES should facilitate re-
endothelialisation. The resultant DES has the ability to be arterially
biocompatible and thus offers predictable safety and performance
proﬁle.
The drug used is sirolimus, which is an ideal choice considering
that it acts on the common ﬁnal pathway of cell division cycle
without an exceptional risk of necrosis induction. It is a macrolide
with cytostatic rather than cytotoxic properties that impedes
advancement from G1 to S in the cell cycle and inhibits the vascular
smooth muscle cell migration and proliferation.19
The biomimicry characteristic of the BioMime SES is main-
tained due to its biodegradable polymer coating of BioPoly-
copolymer. The biodegradable polymer is non-inﬂammatory and
has excellent drug-release kinetics; it is also a right polymer choice
because of its ability to avoid cracking, webbing, lumping or
sticking to the balloon surface.
The safety and efﬁcacy of BioMime SES owing to its biomimicry
design was conﬁrmed by the primary safety and efﬁcacy trials
meriT-1 and meriT-2 for de novo lesions and real-world patients,
respectively.11,12 The meriT-1 study shown that there were no
safety concerns in this preliminary evaluation including absence of
MACE or ST up to 12-months. In addition, the meriT-2 study shown
that the BioMime SES with ultra-thin struts and a biodegradable
polymer demonstrated a high procedural success rate, low late
lumen loss, and sustained safety and efﬁcacy up to 12 months. The
meriT-3 study included 1161 all-comer patients requiring stenting
for the management of CAD. The MACE rate in meriT-3 was 2.35%
at 1-year follow-up. However, longer follow-up of patients
receiving the BioMime SES will be necessary to conﬁrm long-
term safety of this DES. The observational studies are a true
representation of all-comer population, unlike prospective con-
trolled trials which have limitations in terms of a real clinical
picture and have restricted enrollment criteria. Additionally,
observational studies are analyses of an homogeneous group of
subjects who are prospectively followed over a deﬁned period of
time.20
The ongoing concerns related to ST in implanted stents
prompted us to analyze the thrombosis rates with scrutiny in
the present study. Stent thrombosis incidences observed withBioMime SES at 1-year follow-up (0.09%) were low and comparable
with current industry standards like sirolimus-eluting Orsiro stent
(0.4%) and biolimus-eluting Nobori stent (1.2%) at 1-year follow-
up.21
This study has some limitations. One of the chief limitations is
the nature of the study—a retrospective analysis of a post-
marketing study. In addition, a 12-month follow-up period might
not be long enough for the safety and performance of the BioMime
SES. Consequently, further studies with longer follow-up periods,
are necessary.
The present study supports conducting randomized clinical
studies to evaluate the BioMime SES among the other drug-eluting
stents on longer term.
6. Conclusions
The BioMime SES with biodegradable polymer is safe and
effective in a real-world, all-comers CAD patients including those
with high-risk and very complex lesions, indicating low rates of
MACE over 1-year follow-up period.
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